Strathclyde: novel compound for the treatment of psoriasis

Licensing opportunity | Development opportunity

Researchers at Strathclyde University have isolated a novel compound for the treatment of psoriasis from a plant extract of Calendula officinalis (marigold).

The compound has anti-proliferative effects against normal skin cells growing in tissue culture and has cleared initial regulatory toxicology testing. It can be applied locally to affected areas of skin, minimising the chances of systemic side effects.

Although derived from a natural product, the active compound can be synthesised chemically. It has a novel mechanism of action and the researchers say it is economical to manufacture.

The compound is covered by granted US patents. The university is looking for partners who are interested in developing, licensing or exploiting the technology. For more information, visit the project page at: http://www.university-technology.com/details/novel-compound-for-treatment-of-psoriasis